BioSenic SA
Develops therapies for autoimmune diseases, inflammation, and bone disorders.
BIOS | BR
Overview
Corporate Details
- ISIN(s):
- BE0970179827 (+1 more)
- LEI:
- 549300HFIIMTOP1DFR76
- Country:
- Belgium
- Address:
- RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
- Website:
- http://www.biosenic.com/
Description
BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2021-08-27 08:00 |
Bone Therapeutics_PV_AGE4_20210823.pdf
|
French | PDF • 498.0 KB | ||
| 2021-08-06 07:00 |
2EN.Bone Therapeutics_EGM-20210823_Proxy form.pdf
|
English | PDF • 652.1 KB | ||
| 2021-08-06 07:00 |
2FR.Bone Therapeutics_AGE-20210823_Procuration.pdf
|
French | PDF • 659.0 KB | ||
| 2021-08-06 07:00 |
1EN.Bone Therapeutics_EGM-20210823_Convening notice.pdf
|
English | PDF • 436.2 KB | ||
| 2021-08-06 07:00 |
3FR.Bone Therapeutics_AGE-20210823_Information sur les droits des actionnaires.…
|
French | PDF • 201.6 KB | ||
| 2021-08-06 07:00 |
3EN.Bone Therapeutics_EGM-20210823_Information on shareholders rights.pdf
|
English | PDF • 332.8 KB | ||
| 2021-08-06 07:00 |
1FR.Bone Therapeutics_AGE-20210823_Convocation.pdf
|
French | PDF • 538.5 KB | ||
| 2021-08-06 07:00 |
BOTHE_PR_2021-08-06_EGM4_Notice_EN_Final.pdf
|
English | PDF • 178.5 KB | ||
| 2021-08-06 07:00 |
Bone Therapeutics_PV_AGE3_20210805.pdf
|
French | PDF • 461.7 KB | ||
| 2021-07-19 07:00 |
Bone Therapeutics provides update on the progress of clinical studies
|
English | PDF • 188.4 KB | ||
| 2021-07-19 07:00 |
Bone Therapeutics fait le point sur l’avancement de ses études cliniques
|
French | PDF • 204.5 KB | ||
| 2021-07-05 07:00 |
5.Bone Therapeutics_Rapport_spécial_art_7_228_7_229_continuité_Amended.pdf
|
French | PDF • 730.1 KB | ||
| 2021-07-05 07:00 |
2FR.Bone Therapeutics_AGE-20210805_Procuration.pdf
|
French | PDF • 673.4 KB | ||
| 2021-07-05 07:00 |
2EN.Bone Therapeutics_EGM-20210805_Proxy form.pdf
|
English | PDF • 668.1 KB | ||
| 2021-07-05 07:00 |
4.Bone Therapeutics_Rapport Spécial du Conseil d_administration_7_180 7_191 et …
|
French | PDF • 717.3 KB |
Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioSenic SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioSenic SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-16 | Rieger Francois | Board | Sell | 2,500,000 | 25,000.00 EUR |
| 2024-08-06 | Rieger Francois | Board | Sell | 868,653 | 7,186.87 EUR |
| 2024-08-05 | POMI SCHNEITER VERONIQUE | Board | Sell | 534,750 | 4,331.47 EUR |
| 2024-08-02 | POMI SCHNEITER VERONIQUE | Board | Sell | 193,900 | 1,609.37 EUR |
| 2024-08-01 | Rieger Francois | Board | Sell | 1,236,684 | 11,463.87 EUR |
| 2024-08-01 | POMI SCHNEITER VERONIQUE | Board | Sell | 140,003 | 1,246.03 EUR |
| 2024-07-31 | POMI SCHNEITER VERONIQUE | Board | Sell | 503,771 | 4,685.07 EUR |
| 2024-07-30 | POMI SCHNEITER VERONIQUE | Board | Sell | 360,021 | 3,348.20 EUR |
| 2024-07-29 | POMI SCHNEITER VERONIQUE | Board | Sell | 372,893 | 3,430.62 EUR |
| 2024-07-24 | POMI SCHNEITER VERONIQUE | Board | Sell | 2,168,361 | 21,033.10 EUR |
Peer Companies
